Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality. - Cunningham CE; Vizeacoumar FS; Zhang Y; Kyrylenko L; Both S; Maranda V; Dong H; Price JDW; Gao P; Wagner K; Wu Y; Lazell-Wright M; et al. (Cell genomics, 2025)